We’re happy to share that Rashik Aryal, MSc is the latest addition to the Bind Research family! Rashik joins us as Research Assistant, bringing a genuinely multidisciplinary background, from clinical diagnostics to genetic engineering to early-stage protein research. Rashik will be supporting Bind across protein expression and characterisation workflows, while also helping us develop rigorous, […]
1 May 2026
We’re delighted to welcome Mark Murcko, Ph.D. to the Board of Bind Research and our Lead Scientific Advisor. Mark joins Tom Kalil, who was recently appointed Interim Chair of the Board. Tom is CEO of Renaissance Philanthropy, an organisation that has already played a vital role in Bind’s establishment. Mark brings to Bind a deep […]
28 Apr 2026
Got an IDP target? We’d love to hear from you. Intrinsically disordered proteins are implicated in some of the most important and least-treated diseases in human health, but for a long time the tools to drug them simply didn’t exist. At Bind, we’re building those tools, and we want to put them to work on […]
19 Mar 2026
On 19 March 2026, Bind Research officially launched to an audience of more than 300 scientists, investors, policymakers, clinicians and technologists at One Triton Square, London. The event was hosted by VentureCafé London, sponsored by ARIA. The evening featured two keynote speakers. Professor Sheena Radford OBE FRS FMedSci spoke about why intrinsically disordered proteins remain […]
19 Mar 2026
30% of the human proteome is intrinsically disordered. Almost none of it is considered druggable. That is one of the largest unmet opportunities in medicine. Bind has recently published two papers setting out exactly why disordered proteins have resisted drug discovery for so long. The barriers are real: no stable binding pockets, no scalable measurement […]
18 Mar 2026
We’re delighted to welcome three new members in 2026. Dr Hannah Kiely-Collins joins as Senior Scientist, Chemoproteomics. A chemical biologist specialising in chemoproteomics and proximity-inducing modalities, Hannah previously worked at the Francis Crick Institute on translational projects spanning oncology, schizophrenia, and inflammatory bowel disease. At Bind, she will establish a chemoproteomics platform for IDP ligand […]
12 Feb 2026
We’re delighted to announce the appointment of Tom Kalil as our Interim Board Chair in late 2025. Throughout his career, Tom has been a champion for strengthening investment in the science and technology. His unique blend of government experience, private-sector insight, and philanthropic leadership makes him ideally positioned to guide Bind Research through this critical […]
21 Dec 2025
Bind just published it’s first newsletter, summarising all the exciting things happening in the last few months.
19 Dec 2025
We have welcomed a further four new team members this last month into pivotal roles for Bind.
6 Oct 2025
Bind has taken up a lease for 2,746 sq. ft of state-of-the-art lab and office space at the Apex Building, Tribeca.
2 Oct 2025
Over the last 3 months we are delighted to have welcomed five stellar new members of the team to Bind.
1 Sep 2025
It’s been an exciting week at Bind Research! We’re thrilled to welcome three exceptional people to the team.
6 Jun 2025
Earlier this week, we announced the launch of Bind Research, a new not-for-profit organisation dedicated to delivering tools and datasets to make disordered proteins druggable.
12 Feb 2025
London, UK – 11 February 2025 – Bind Research was today launched as the UK’s first not-for-profit Focused Research Organisation (FRO)
11 Feb 2025
Bind Research has officially incorporated, marking a significant milestone as it embarks on its mission to drive breakthrough advancements targeting intrinsically disordered proteins.
9 Jan 2025
Bind is pitching at the Investor Event for the Research Ventures Catalyst programme. Find us at the Francis Crick Institute on July 23rd (more information here).
11 Jul 2024
Bind Research is excited to welcome Dr Marcus Harrison as Chief Operating Officer.
26 Jun 2024
Bind Research is delighted to welcome Melissa Strange in her new role as Chief Financial Officer.
25 Jun 2024
Bind is a finalist in the UK Department for Science, Innovation, and Technology (DSIT) Research Ventures Catalyst programme.
11 Jun 2024
Bind is pitching in the UK Department for Science, Innovation, and Technology (DSIT) Research Ventures Catalyst programme at the Royal Society of Chemistry.
18 Jan 2024
